Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QuetiaFlex
- Development stage
- Preclinical
- Lead developer
- Altus Formulation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
QuetiaFlex is an extended-release formulation of the atypical antipsychotic quetiapine, developed by Altus Formulation using its proprietary FLEXITAB technology. This technology enables the production of breakable, once-daily extended-release tablets, providing clinicians and patients with dosing flexibility while maintaining a controlled-release profile. Quetiapine, the active ingredient, functions as an antagonist at multiple neurotransmitter receptors, most notably the dopamine D2 and serotonin 5-HT2A receptors. It is typically indicated for the treatment of schizophrenia and bipolar disorder. As a "Value-Added Medicine," QuetiaFlex is positioned as a cost-effective reformulation designed for quick market entry through in-licensing partnerships.
- Brand names
- QuetiaFlex
- Other names
- quetiapine XRquetiapine extended-release breakable tablet
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ADRA1A (α1A)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on QuetiaFlex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QuetiaFlex.